Help paying · Medicare negotiated price · pharmacy cost · cycle 2027
Ibrance (palbociclib): where help paying exists, what Medicare negotiated and what pharmacies pay
1 assistance program lists palbociclib, each with its income ceiling and when we read it. Medicare's negotiated price for a 30-day supply is $7,871 on January 1, 2027. 2 non-manufacturing label changes are dated in the last 12 months in the FDA's file. The FDA's enforcement reports name this drug's packages in 1 recall entry. ClinicalTrials.gov lists 61 recruiting trials that name palbociclib.
Every package we can price
Per-unit prices (per unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00069-0187-21 | Ibrance (Palbociclib) 75mg Cap | n/a | n/a | $381 | n/a | no NADAC price |
| 00069-0188-21 | Ibrance (Palbociclib) 100mg Cap | n/a | n/a | $381 | n/a | no NADAC price |
| 00069-0189-21 | Ibrance (Palbociclib) 125mg Cap | n/a | n/a | $381 | n/a | no NADAC price |
| 00069-0284-03 | IBRANCE 75MG FCT 3X7 BLS US | n/a | n/a | $381 | n/a | no NADAC price |
| 00069-0284-07 | IBRANCE 75MG FCT BLS US | n/a | n/a | $381 | n/a | no NADAC price |
| 00069-0486-03 | IBRANCE 100MG FCT 3X7 BLS US | n/a | n/a | $381 | n/a | no NADAC price |
| 00069-0486-07 | IBRANCE 100MG FCT BLS US | n/a | n/a | $381 | n/a | no NADAC price |
| 00069-0688-03 | IBRANCE 125MG FCT 3X7 BLS US | n/a | n/a | $381 | n/a | no NADAC price |
| 00069-0688-07 | IBRANCE 125MG FCT BLS US | n/a | n/a | $381 | n/a | no NADAC price |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA207103 | Ibrance, Ibrance (palbociclib) 125mg Cap | August 8, 2034 | June 24, 2029 | August 8, 2034 | patent 10723730 with its pediatric extension; 21 dated entries listed |
| NDA212436 | Ibrance 100mg Fct 3x7 Bls Us, Ibrance 125mg Fct 3x7 Bls Us, Ibrance 75mg Fct 3x7 Bls Us | February 19, 2037 | June 24, 2029 | February 19, 2037 | patent 11065250 with its pediatric extension; 27 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Ibrance of $2.04 billion in 2024, across 131,537 claims and 15,923 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $2.04 billion | 131,537 | 15,923 | $15,471 |
| 2023 | $2.02 billion | 128,974 | 16,015 | $15,669 |
| 2022 | $1.95 billion | 134,834 | 17,497 | $14,450 |
| 2021 | $1.89 billion | 140,478 | 18,781 | $13,464 |
| 2020 | $2.11 billion | 165,133 | 21,394 | $12,771 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 7 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| KY | 87 | $1,169,483 | Fee-for-service only |
| CA | 77 | $1,140,187 | All record types |
| NJ | 68 | $1,082,027 | All record types |
| WV | 63 | $1,012,285 | All record types |
| CT | 55 | $938,370 | All record types |
| NC | 51 | $839,952 | Fee-for-service only |
| IL | 52 | $647,765 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (3 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 81 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Programs in our finder that list palbociclib. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Pfizer RxPathways manufacturer
Income at or below 300% FPL ($47,880 for one person in 2026)
Ceiling matched against the program's page text, November 6, 2026.Status. Pfizer RxPathways lists the products that remain in its Patient Assistance Program as of January 1, 2026, and marks Xeljanz and Bosulif as taking no new patients starting July 1, 2026. The page also notes the product list is subject to change. (read November 7, 2026)
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
FDA actions on the applications behind Ibrance dated since November 11, 2025, leaving out manufacturing (CMC) changes. 2 changes in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| June 24, 2026 | Efficacy | NDA207103 | 24 | Label (PDF) posted June 29, 2026FDA letter posted June 26, 2026 |
| June 24, 2026 | Efficacy | NDA212436 | 12 | Label (PDF) posted June 29, 2026FDA letter posted June 26, 2026 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Safety notices
FDA enforcement report entries that name a package of Ibrance by its NDC: 1 entry, newest first. FDA assigns each a class by health risk: Class I is the most serious and Class III the least. An entry records what the recalling firm reported and FDA classified; it is not advice about any package you hold.
| Reported | Class | Status | Recalling firm | Reason (shortened) | Packages named |
|---|---|---|---|---|---|
| May 16, 2018D-0777-2018 | Class II | Terminated | Kroger Specialty Pharmacy, Inc. | Lack of Processing Controls. | 1 |
Source: openFDA drug enforcement reports, file read November 7, 2026. openFDA data file. All recent recalls across these drugs: drug recalls feed.
Clinical trials recruiting
ClinicalTrials.gov lists 61 interventional trials that name palbociclib and are recruiting, and 20 more not yet recruiting. By phase: Phase 2: 22, PHASE1/PHASE2: 15, Phase 3: 9, Phase 1: 8, Not applicable: 6, Early phase 1: 1. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT03424005 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerMetastatic Breast Cancer | Phase 1 / Phase 2 | Hoffmann-La Roche | November 6, 2026 | United States, Australia, France and 6 more |
| NCT06126276 | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)Malignant Female Reproductive System Neoplasm; Malignant Solid Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm | Phase 2 | National Cancer Institute (NCI) | November 5, 2026 | United States, Puerto Rico |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Breast Neoplasms; Neoplasm Metastasis | Phase 3 | Eli Lilly and Company | November 4, 2026 | United States, Argentina, Australia and 7 more |
| NCT04802759 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerInoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | Phase 1 / Phase 2 | Hoffmann-La Roche | November 3, 2026 | United States, Australia, Israel and 2 more |
| NCT06377852 | The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyMetastatic Breast Cancer | Phase 3 | American Society of Clinical Oncology | November 2, 2026 | United States |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialAdvanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | National Cancer Institute (NCI) | November 2, 2026 | United States, Puerto Rico |
| NCT06380751 | Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerAdvanced Breast Cancer | Phase 3 | AstraZeneca | October 30, 2026 | United States, Argentina, Australia and 7 more |
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationMetastatic Breast Cancer | Phase 3 | LeonaBio | October 29, 2026 | United States, Australia, Belgium and 7 more |
| NCT07492641 | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseHR+/HER2- Breast Cancer | Phase 3 | BeOne Medicines | October 26, 2026 | United States, Australia, Brazil and 7 more |
| NCT04606446 | Study of PF-07248144 in Advanced or Metastatic Solid TumorsLocally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | Pfizer | October 21, 2026 | United States, Australia, China and 2 more |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Ibrance?
The CMS file publishes $7,871 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
The two CMS files do not give a comparable per-unit price for this drug.
Is there help paying for Ibrance?
1 assistance program lists it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
When could a generic version of Ibrance arrive?
For Ibrance, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA207103, August 8, 2034; NDA212436, February 19, 2037. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Ibrance?
ClinicalTrials.gov lists 61 recruiting interventional trials that name palbociclib (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Ibrance?
CMS's Medicare Part D spending dataset reports gross spending on Ibrance of $2.04 billion in 2024, across 131,537 claims and 15,923 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/ibrance.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; openFDA drug enforcement reports; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.